Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 6 August 2024, 12:15 HKT/SGT
Share:
    

Source: Eisai
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation

TOKYO, Aug 6, 2024 - (JCN Newswire) - Eisai Co., Ltd. reconfirmed that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (generic name:lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows.

The SC formulation (including initiation and maintenance dosing) received Fast Track designation from the

U.S. Food and Drug Administration (FDA). In agreement with the FDA, Eisai initiated a rolling submission and review for SC maintenance dosing in May 2024. In parallel, discussions are ongoing with the FDA regarding optimal dosage and the fastest regulatory pathway for the SC initiation dosing. There are no changes to the previously announced timeline for the SC application at this time. We expect to complete the rolling application for SC maintenance dosing in the third quarter of fiscal year 2024 ending March 2025, with a review period of six months if designated for priority review or ten months under standard review. For SC initiation dosing, we aim to obtain a regulatory approval by the end of fiscal year 2025 ending March 2026.

A supplemental Biologics License Application (sBLA) for intravenous (IV) maintenance dosing was submitted to the FDA in March 2024 and accepted in June of the same year. The PDUFA (Prescription Drugs User Fee Act) action date is set for January 25, 2025.

Eisai is committed to making the IV maintenance dosing and SC formulation available as new treatment options to people with early AD as soon as possible.

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
Oct 16, 2024 18:14 HKT/SGT
Amyotrophic Lateral Sclerosis Treatment "Rozebalamin(R) for Injection 25 mg" Receives The Good Design Award 2024 for Light- Proof Vial Packaging
Oct 8, 2024 13:00 HKT/SGT
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia
Oct 2, 2024 10:28 HKT/SGT
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia
Sept 24, 2024 15:06 HKT/SGT
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: